A novel isolator-based system promotes viability of human embryos during laboratory processing., in women undergoing in vitro fertilisation.

Expression of Osteoblast–Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines.

One of the main obstacles to the effective treatment of ovarian cancer patients continues to be the drug resistance of cancer cells. Osteoblast-Specific Factor 2 (OSF-2, Periostin) is a secreted extracellular matrix protein (ECM) expressed in fibroblasts during bone and teeth development. Expression of OSF-2 has been also related to the progression and drug resistance of different tumors.
The present study investigated the role of OSF-2 by evaluating its expression in the primary serous ovarian cancer cell line, sensitive (W1) and resistant to doxorubicin (DOX) (W1DR) and methotrexate (MTX) (W1MR). The OSF-2 transcript (real-time PCR analysis), protein expression in cell lysates and cell culture medium (western blot), and expression of the OSF-2 protein in cell lines (immunofluorescence) were investigated in this study. Increased expression of OSF-2 mRNA was observed in drug-resistant cells and followed by increased protein expression in cell culture media of drug-resistant cell lines.
A subpopulation of ALDH1A1-positive cells was noted for W1DR and W1MR cell lines; however, no direct co-expression with OSF-2 was demonstrated. Both drugs induced OSF-2 expression after a short period of exposure of the drug-sensitive cell line to DOX and MTX.
The obtained results indicate that OSF-2 expression might be associated with the development of DOX and MTX resistance in the primary serous W1 ovarian cancer cell line.
A novel isolator-based system promotes viability of human embryos during laboratory processing., in women undergoing in vitro fertilisation.

Antibody-free detection of phosphoserine/threonine containing peptides by homogeneous time-resolved fluorescence.

Protein phosphorylation is a critical signaling mechanism in cellular regulation and stress response, and more than 95% of the phosphorylations are targeted toward Ser or Thr amino-acid residues. The classical techniques for analyzing phospho-amino acid residues use radioisotopes or sequence-specific antibodies.
However, both practical and economical limitations have prevented their development, and we here propose an original approach for the detection of phospho-Ser/Thr residues.
It requires no antibody and exploits the patented homogeneous time-resolved fluorescence (HTRF) technology, in association with a 3-step chemical transformation of phospho-amino acids into fluorescent derivatives.
The process involves: (i) alkaline β-elimination of the phosphorylated group, (ii) Michael addition of a bifunctional group, and then (iii) introduction of cyanin-5 as fluorescent acceptor for HTRF. The donor fluorescent moiety at the N-terminus of the phosphorylated peptide is a streptavidin europium cryptate conjugate.
After its development, the detection system has been validated on synthetic peptide substrates of Chk2, a key protein kinase activated in response to DNA damage and involved in cell cycle arrest.
The results showed a good correlation with known specificity profiles. Interestingly, the detection system is versatile, easy to implement, and suitable for multiple parallel analyses.

Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies.

Agonist-stimulated desensitization of the beta2-adrenergic receptor (beta2AR) is caused by both a potent cAMP-dependent protein kinase (PKA)-mediated phosphorylation and a less potent, occupancy-dependent, G protein-coupled receptor kinase (GRK)-mediated phosphorylation that leads to beta-arrestin binding and internalization.
In this study the kinetics of phosphorylation of the third intracellular loop PKA site Ser262 and the putative C-tail GRK sites Ser355, Ser356 of the human beta2AR overexpressed in human embryonic kidney (HEK) 293 cells were characterized using phosphoserine-specific antibodies.
Specificity of the antibodies was shown by their lack of reactivity with mutant beta2ARs lacking the respective sites. In addition, overexpression of GRK2 and GRK5 increased basal levels of phosphorylation of the GRK sites Ser355, Ser356 in both COS-7 and HEK 293 cells. Epinephrine, prostaglandin E1, and forskolin at maximum concentrations stimulated phosphorylation of the beta2AR PKA site (Ser262) by 4-fold, whereas PMA stimulated it by 2-fold. Epinephrine stimulated PKA site phosphorylation with an EC50 of 20 to 40 pM. In contrast, epinephrine stimulated GRK site phosphorylation (Ser355,Ser356) with an EC50 of 200 nM (1-min treatments), which is more than 4000-fold higher relative to PKA site phosphorylation, consistent with an occupancy-driven process. After 10 to 30 min, the EC50 for epinephrine stimulation of GRK site phosphorylation was reduced to 10 to 20 nM but was still approximately 200-fold greater than for the PKA site.
The EC50 for internalization correlated with GRK site phosphorylation and showed a similar shift with time of epinephrine stimulation. The kinetics of epinephrine-stimulated GRK site phosphorylation were not altered in a mutant of the beta2AR lacking the PKA consensus sites.
The initial levels (2 min) of a range of agonist-stimulated GRK site phosphorylations were correlated with their efficacy for activation of adenylyl cyclase, namely epinephrine>> or = formoterol = fenoterol>> terbutaline = zinterol = albuterol>> salmeterol>> dobutamine>> or = ephedrine. However, after 20 to 30 min of treatment, agonists with intermediate strengths, such as albuterol and salmeterol, stimulate GRK site phosphorylations that are approximately equal to that produced by epinephrine, and the correlation breaks down.
The GRK and PKA site antibodies were also effective in detecting phosphorylation of the endogenous beta2AR expressed in A431 human epidermoid carcinoma cells.
To summarize, our results show a remarkable amplification of PKA site phosphorylation relative to the putative GRK site phosphorylation, heterologous stimulation of the PKA site phosphorylation, no dependence of GRK site phosphorylation on PKA sites, and a reasonable correlation of initial levels of GRK site phosphorylation with the strength of a range of agonists.

Changes in anti-phosphoserine and anti-phosphothreonine antibody binding during the sleep-waking cycle and after lesions of the locus coeruleus.

Cellular responses to many extracellular signals occur through phosphorylation or dephosphorylation of intracellular proteins.
To determine whether changes in protein phosphorylation accompany the electrophysiological changes occurring during the sleep-waking cycle, immunocytochemical mapping of cells labeled with anti-phosphoserine and anti-phosphothreonine antibodies was performed on brain sections of sleeping and waking rats.
Animals implanted for chronic polysomnographic recordings were sacrificed after either 3h of sleep or 3h of sleep deprivation by gentle handling.
Anti-phosphoserine and anti-phosphothreonine staining was mainly localized in neurons and was high in some brain regions, such as cerebral cortex and hypothalamus, and low in others, such as the thalamus. In all cases, the number of cells labeled with either antibody in the cerebral cortex was markedly higher in rats sacrificed after 3h of waking than in rats sacrificed after 3h of sleep.
Unilateral lesions of the locus coeruleus by local injection of 6-hydroxydopamine were performed in other animals to determine whether the increase in protein phosphorylation during waking was influenced by the activity of the noradrenergic system, which is higher in waking than in sleep.
In animals sacrificed after 3h of spontaneous or forced waking, the number of labeled neurons in the cerebral cortex was decreased on the side in which noradrenergic fibers had been lesioned.
These results suggest that 1) neurons exist physiologically in different states of phosphorylation, ranging from a state of very high phosphorylation (e.g., in the cerebral cortex) to a state of very low phosphorylation (e.g., in many thalamic nuclei); 2) the fraction of highly phosphorylated neurons in cerebral cortex is higher in waking than in sleep and 3) part of the immunoreactive phosphorylation present in highly labeled cortical neurons is controlled by the locus coeruleus.

Identification of a high-affinity anti-phosphoserineantibody for the development of a homogeneous fluorescence polarization assay of protein kinase C.

In the last few years, fluorescence polarization (FP) has been applied to the development of robust, homogeneous, high throughput assays in molecular recognition research, such as ligand-protein interactions.
Recently, this technology has been applied to the development of homogeneous tyrosine kinase assays, since there are high-affinity anti-phosphotyrosine antibodies available.
Unlike tyrosine kinases, application of FP to assay development for serine/threonine kinases has been impeded because of lack of high-affinity anti-phosphoserine/threonine antibodies. In the present study, we report the discovery of a high-affinity, monoclonal anti-phosphoserine antibody, 2B9, with a Kd of 250 +/- 34 pM for a phosphoserine-containing peptide tracer, fluorescein-RFARKGS(PO(4))LRQKNV. Our data suggest that 2B9 is selective for fluorescein-RFARKGS(PO(4))LRQKNV. The antibody and tracer have been used for the development of a competitive FP assay for protein kinase C (PKC) in 384-well plates.
Phosphatidylserine, which enhances the kinase activity of PKC in a Ca(2+)-dependent manner and has a structure similar to that of phosphoserine, did not interfere with binding of the peptide tracer to the antibody in the FP assay.
The data indicate that the FP assay is more sensitive and robust than the scintillation proximity assay for PKC. The FP assay developed here can be used for rapid screening of hundreds of thousands of compounds for discovery of therapeutic leads for PKC-related diseases.

Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody.

Human progesterone receptor (PR) is phosphorylated on multiple serine residues (at least seven sites) in a manner that involves distinct groups of sites coordinately regulated by hormone and different kinases. Progress on defining a functional role for PR phosphorylation has been hampered both by the complexity of phosphorylation and the lack of simple, nonradioactive methods to detect the influence of ligands and other signaling pathways on specific PR phosphorylation sites in vivo.
Toward this end, we have produced monoclonal antibodies (MAbs) that recognize specific phosphorylation sites within human PR including a basal site at Ser 190 (MAb P190) and a hormone-induced site at Ser 294 (MAb P294).
Biochemical experiments showed the differential reactivity of the P190 and P294 MAbs for phosphorylated and unphosphorylated forms of PR. Both MAbs recognize specific phosphorylated forms of PR under different experimental conditions including denatured PR protein by Western blots and PR in its native conformation in solution or complexed to specific target DNA.
As detected by Western blot of T47D cells treated with hormone for different times, hormone-dependent down-regulation of total PR and the Ser 190 phosphorylation site occurred in parallel, whereas the Ser 294 phosphorylation site was down-regulated more rapidly. This difference in kinetics suggests that the Ser 294 site is more labile than basal sites and is acted upon by distinct phosphatases.
A strong preferential hormone-dependent phosphorylation of Ser 294 was observed on PR-B as compared with the amino-terminal truncated A form of PR.
This was unexpected because Ser 294 and flanking sequences are identical on both proteins, suggesting that a distinct conformation of the N-terminal domain of PR-A inhibits phosphorylation of this site.
That Ser 294 lies within an inhibitory domain that mediates the unique repressive functions of PR-A raises the possibility that differential phosphorylation of Ser 294 is involved in the distinct functional properties of PR-A and PR-B.

Anti-phosphoserine and anti-phosphothreonine antibodies modulate autophosphorylation of the insulin receptor but not EGF receptor.

We examined the effect of anti-phosphothreonine and anti-phosphoserine antibodies on insulin receptor autophosphorylation. These antibodies did not affect insulin binding activity of the receptor. These antibodies, however, inhibited insulin-stimulated autophosphorylation of insulin receptor, while did not affect EGF-stimulated autophosphorylation of EGF receptor.

Phosphoserine Antibody
20-abx134715 Abbexa
  • 427.20 EUR
  • 644.40 EUR
  • 260.40 EUR
  • 100 ul
  • 200 ul
  • 30 ul

Phosphoserine Antibody
abx448438-400ul Abbexa 400 ul 644.4 EUR

Phosphoserine antibody
10R-7895 Fitzgerald 100 ug 386.4 EUR

Phosphoserine antibody
10R-P125a Fitzgerald 250 ul 807.6 EUR

Phosphoserine antibody
20C-CR1332RP Fitzgerald 100 ug 159.6 EUR

Phosphoserine antibody
70R-PR015 Fitzgerald 50 ug 289.2 EUR

Phosphoserine Antibody
abx020673-100ug Abbexa 100 ug 1279.2 EUR

Phosphoserine Antibody
20-abx159643 Abbexa
  • 326.40 EUR
  • 276.00 EUR
  • 100 ug
  • 50 ug

Phosphoserine Antibody
E38PA9207 EnoGene 100ul 225 EUR

Phosphoserine Antibody (APC)
abx448359-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (RPE)
abx448401-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (HRP)
abx448439-400ul Abbexa 400 ul 727.2 EUR

Phosphoserine Antibody (FITC)
abx448373-400ul Abbexa 400 ul 693.6 EUR

Phosphoserine Antibody (PerCP)
abx448393-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (Biotin)
abx448367-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine antibody (biotin)
60R-PR001bt Fitzgerald 100 ug 1008 EUR

Phosphoserine Antibody (ATTO 390)
abx448287-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 488)
abx448295-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 565)
abx448303-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 594)
abx448311-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 633)
abx448319-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 655)
abx448327-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 680)
abx448335-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (ATTO 700)
abx448343-400ul Abbexa 400 ul 710.4 EUR

Phosphoserine Antibody (Streptavidin)
abx448409-400ul Abbexa 400 ul 710.4 EUR

Antibody for Phosphoserine
SPC-149F Stressmarq 0.4ml 434.4 EUR

Antibody for Phosphoserine
SPC-149F-A390 Stressmarq 0.4ml 490.8 EUR
The inhibition was reversed by adding large amounts of phosphoserine or phosphothreonine. These data suggest that phosphoserine and phosphothreonine on insulin receptor play an important role in insulin-induced conformational change of the receptor.
A novel isolator-based system promotes viability of human embryos during laboratory processing., On the fate of primordial germ cells injected into early mouse embryos.

Polyclonal and monoclonal antibodies against chicken gizzard 5‘-nucleotidase inhibit the spreading process of chicken embryonic fibroblasts on laminin substratum.

Polyclonal and monoclonal antibodies raised against chicken gizzard 5′-nucleotidase were tested in adhesion assays of embryonic chicken fibroblasts (CEF) for their ability to interfere with the adhesion process of these cells on either laminin or fibronectin substrata. The initial attachment process of CEF on fibronectin and laminin substrata was not influenced by preincubating these cells with antibodies against chicken gizzard 5′-nucleotidase.
However, the subsequent spreading process of these cells was found to be inhibited for at least 2 h on a laminin substratum. This effect was obtained with a polyclonal antibody as well as with one from 12 monoclonal antibodies raised against the native enzyme purified from chicken gizzard.
In vitro assays demonstrated a competition of laminin and this monoclonal antibody for the binding site on purified 5′-nucleotidase. Spreading-arrested and rounded CEF do not develop prominent intracellular stress-fibers like control cells, instead they seem to concentrate their available actin in areas of presumptive initial contact with the laminin substratum.

Clinical and immunological heterogeneity of canine subepidermal blistering dermatoses with anti-<em>laminin</em>-332 (<em>laminin</em>-<em>5</em>) auto-<em>antibodies</em>.

Laminin-332 (laminin-5) is a basement membrane heterotrimeric protein composed of alpha-3, beta-3 and gamma-2 laminin chains. Laminin-332 polypeptides are targeted by auto-antibodies in human patients with mucous membrane (cicatricial) pemphigoid or, more rarely, subepidermal vesicular diseases that resemble epidermolysis bullosa acquisita (EBA) or bullous pemphigoid (BP).
The objectives of this report were to characterize the clinical, histopathological and immunological characteristics of nine dogs with auto-antibodies targeting laminin-332. Immunological investigations consisted of direct immunofluorescence (IF), indirect IF with intact and salt-split canine gingival, and salt-split normal or laminin-332-deficient human skin, immunoblotting with purified human laminin-332 and immunoblotting with recombinant NC1 domain of human collagen VII.
All dogs exhibited varying degrees of skin blistering and ulceration associated with microscopic subepidermal vesiculation with or without inflammatory cells. Indirect IF established that circulating IgG auto-antibodies bound the dermal side of salt-split canine lip and human skin. In five dogs, IgG variably recognized the basement membrane of laminin-332-deficient human skin (three dogs negative, two dogs positive).
In all nine dogs, IgG auto-antibodies detected purified human laminin-332 by immunoblotting. In two dogs, additional targeting of collagen VII-NC1 was present.
These observations establish laminin-332 as a novel basement membrane antigen in dogs with autoimmune blistering diseases with variable clinical phenotypes. The names ‘acquired junctional epidermolysis bullosa’, ‘anti-laminin-332 mucous membrane pemphigoid (MMP)’ and ‘mixed auto-immune subepidermal blistering dermatosis’ are proposed for dogs with clinical signs reminiscent of EBA, MMP or BP respectively.

Bullous pemphigoid positive for anti-BP180 and anti-<em>laminin</em> <em>5</em> <em>antibodies</em> in a patient with graft-vs-host disease.

We report the case of a 55-year-old female with bullous pemphigoid (BP) who was positive for anti-BP180 and anti-laminin 5 antibodies after development of graft-vs-host disease (GVHD) caused by a bone marrow transplant. She had tense blisters on her trunk and extremities.
Histologic examination showed a subepidermal blister and marked lymphocytic infiltration, especially eosinophils. Direct immunofluorescence revealed a linear deposition of IgG on the base membrane zone. Indirect immunofluorescence on 1M NaCl split skin revealed a linear IgG deposition to both sides of the epidermal and the dermal layers.
Immunoblot assays using human epidermal extracts and BP180 NC16a domain recombinant protein confirmed the presence of IgG antibodies against BP180 and recombinant BP180 NC16a domain protein. Furthermore, immunoblotting using laminin 5 purified from human keratinocyte extract as the substrate demonstrated reactivity against the gamma2 and beta3 subunits but not the alpha3 subunit of laminin 5.
We diagnosed BP and treated her with prednisolone (40 mg/day). Both skin and oral lesions resolved without leaving scars on the bulla. Immune disturbance as well as destruction of basal epidermal cells and base membrane by GVHD may result in the induction of autoimmune blistering diseases with unusual clinical and laboratory manifestations.

Ocular ‘non-scarring’ mucous membrane pemphigoid associated with anti-<em>laminin</em>-<em>5</em> <em>antibodies</em>.

Mucous membrane pemphigoid is a rare, chronic autoimmune disease characterized by subepidermal blistering and scarring, predominantly affecting mucous membranes. Ocular involvement frequently occurs and often represents the only manifestation of the disease.
We describe a 62-year-old woman with a bilateral 18-month duration of conjunctival hyperaemia, associated with erythema and oedema of the eyelids, lacking any typical ocular signs of mucous membrane pemphigoid such as sub-conjuctival fibrosis and scarring. Histology was not significant.
Direct immunofluorescence of the conjunctiva showed IgG, IgA and complement deposition along the basement membrane zone. Immunoprecipitation analysis of affinity purified laminin-5 revealed a band consistent with the beta3 chain of laminin-5. This represents the first case of pure ocular mucous membrane pemphigoid associated with anti-laminin-5 antibodies.

Detection of <em>laminin</em> <em>5</em>-specific auto-<em>antibodies</em> in mucous membrane and bullous pemphigoid sera by ELISA.

Mucous membrane pemphigoid (MMP) is an autoimmune bullous disease that primarily affects mucous membranes leading to a scarring phenotype. MMP patients produce auto-antibodies (auto-ab) that preferentially recognize two components of the dermoepidermal basement membrane zone (BMZ): bullous pemphigoid (BP)180 and laminin 5 (LN5). Since detection of disease-specific auto-ab may be critical for the diagnosis of MMP, we developed an ELISA with affinity-purified native human LN5. A total of 24 MMP, 72 BP, and 51 control sera were analyzed for LN5-specific auto-ab: 18/24 (75.0%) MMP and 29/72 (40.3%) BP sera were LN5 reactive.
Sensitivity and specificity of the LN5 ELISA for MMP were 75% and 84.3%, respectively, and 40.3% and 88.2% for BP, respectively.
The LN5 ELISA was more sensitive than a dot blot assay with native LN5, which detected LN5-reactive IgG in 14/24 (58.3%) MMP and 16/72 (22.2%) BP sera. In MMP, but not BP, levels of LN5-reactive IgG correlated with disease severity. Furthermore, IgG reactivity to LN5 of the MMP and BP sera was not significantly associated with IgG reactivity against other autoantigens of the BMZ, such as BP180 or BP230. Thus, the established LN5 ELISA holds great promise as a novel diagnostic and prognostic parameter for MMP.

<em>Antibody</em>-induced activation of beta1 integrin receptors stimulates cAMP-dependent migration of breast cells on <em>laminin</em>-<em>5</em>.

The beta1 integrin-stimulating antibody TS2/16 induces cAMP-dependent migration of MCF-10A breast cells on the extracellular matrix protein laminin-5. TS2/16 stimulates a rise in intracellular cAMP within 20 min after plating. Pertussis toxin, which inhibits both antibody-induced migration and cAMP accumulation, targets the Galphai3 subunit of heterotrimeric G proteins in these cells, suggesting that Galphai3 may link integrin activation and migration via a cAMP signaling pathway.

Anti-epiligrin cicatricial pemphigoid with <em>antibodies</em> against the gamma2 subunit of <em>laminin</em> <em>5</em>.

BACKGROUND
Cicatricial pemphigoid (CP) is a scarring subepithelial mucocutaneous blistering disease characterized by anti-basement membrane zone autoantibodies. Anti-epiligrin CP is an uncommon variant that has been recently characterized. Severe laryngeal involvement is infrequently observed in all forms of CP and has been documented in only 2 patients with anti-epiligrin CP.

Laminin 5 Antibody
abx020892-100ug Abbexa 100 ug 1629.6 EUR

Laminin alpha 5 antibody
70R-49989 Fitzgerald 100 ul 292.8 EUR

Laminin ?-5 Polyclonal Antibody
ES6077-100ul ELK Biotech 100ul 334.8 EUR

Laminin ?-5 Polyclonal Antibody
ES6077-50ul ELK Biotech 50ul 248.4 EUR

Laminin Alpha 5 (LAMa5) Antibody
20-abx173303 Abbexa
  • 1028.40 EUR
  • 526.80 EUR
  • 1 mg
  • 200 ug

Laminin Alpha 5 (LAMa5) Antibody
20-abx177308 Abbexa
  • 1446.00 EUR
  • 693.60 EUR
  • 1 mg
  • 200 ug

Laminin, Alpha 5 (LAMA5) Antibody
abx216513-100ug Abbexa 100 ug 526.8 EUR

Laminin Alpha 5 (LAMA5) Antibody
20-abx325869 Abbexa
  • 376.80 EUR
  • 292.80 EUR
  • 100 ug
  • 50 ug

Laminin, Alpha 5 (LAMA5) Antibody
20-abx014033 Abbexa
  • 376.80 EUR
  • 117.60 EUR
  • 477.60 EUR
  • 594.00 EUR
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Laminin Alpha 5 (LAMa5) Antibody
20-abx101531 Abbexa
  • 526.80 EUR
  • 159.60 EUR
  • 1479.60 EUR
  • 710.40 EUR
  • 393.60 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Laminin Alpha 5 (LAMA5) Antibody
20-abx339132 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Laminin, Alpha 5 (LAMA5) Antibody
abx432909-200ul Abbexa 200 ul 343.2 EUR

Laminin Alpha 5 (LAMA5) Antibody
20-abx009049 Abbexa
  • 360.00 EUR
  • 526.80 EUR
  • 226.80 EUR
  • 100 ul
  • 200 ul
  • 30 ul

Laminin, Alpha 5 (LAMA5) Antibody
20-abx304327 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Laminin α-5 Polyclonal Antibody
E20-72527 EnoGene 100ug 225 EUR

Laminin Antibody
20-abx100044 Abbexa
  • 477.60 EUR
  • 159.60 EUR
  • 1328.40 EUR
  • 644.40 EUR
  • 376.80 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Laminin antibody
10R-2067 Fitzgerald 100 ul 457.2 EUR

Laminin antibody
10R-7867 Fitzgerald 100 ug 386.4 EUR

Laminin antibody
10R-8080 Fitzgerald 100 ug 535.2 EUR

Laminin antibody
20R-LR009 Fitzgerald 250 uL 633.6 EUR

Laminin Antibody
abx022767-05ml Abbexa 0.5 ml 1378.8 EUR

Laminin Antibody
R30047 NSJ Bioreagents 100 ug 356.15 EUR

Laminin Alpha-5 Polyclonal Antibody
ABP55078-003ml Abbkine 0.03ml 189.6 EUR

Laminin Alpha-5 Polyclonal Antibody
ABP55078-01ml Abbkine 0.1ml 346.8 EUR

Laminin Alpha-5 Polyclonal Antibody
ABP55078-02ml Abbkine 0.2ml 496.8 EUR

Laminin, Alpha 5 (LAMA5) Antibody (HRP)
20-abx304328 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Laminin, Alpha 5 (LAMA5) Antibody (FITC)
20-abx304329 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
METHODS
We report a case of CP exhibiting extensive laryngeal and ocular involvement. Histological, immunofluorescence, and immunoprecipitation studies confirmed the diagnosis of anti-epiligrin CP. Immunoblotting studies demonstrated the presence of antibodies against the alpha3 and the gamma2 subunit of laminin 5.
CONCLUSIONS
This article expands the diversity of the clinical and immunopathologic features of this newly characterized variant of CP.
A novel isolator-based system promotes viability of human embryos during laboratory processing., in women undergoing in vitro fertilisation.

Using a Syrian (Golden) Hamster Biological Model for the Evaluation of Recombinant Anthrax Vaccines

In this paper, we demonstrate that a Syrian hamster biological model can be applied to the study of recombinant anthrax vaccines. We show that double vaccination with recombinant proteins, such as protective antigen (PA) and fusion protein LF1PA4, consisting of lethal factor I domain (LF) and PA domain IV, leads to the production of high titers of specific antibodies and to protection from infection with the toxicogenic encapsulated attenuated strain B. anthracis 71/12.
In terms of antibody production and protection, Syrian hamsters were much more comparable to guinea pigs than mice. We believe that Syrian hamsters are still underestimated as a biological model for anthrax research, and, in some cases, they can be used as a replacement or at least as a complement to the traditionally used mouse model.

Vaccination with a Brucella ghost developed through a double inactivation strategy provides protection in Guinea pigs and cattle

Vaccination can prevent and control animal brucellosis. Currently, live attenuated vaccines are extensively used to prevent Brucella infection. However, traditional vaccines such as live attenuated vaccines are associated with biological safety risks for both humans and animals. The bacterial ghost (BG) is a new form of vaccine with great prospects. However, bacterial cells cannot be completely inactivated by biological lysis https://www.joplink.net/guinea-pig-antibodies/, conferring a safety risk associated with the vaccine.
In this study, we developed a Brucella abortus A19 bacterial ghost (A19BG) through a double inactivation strategy with sequential biological lysis and hydrogen peroxide treatment. This strategy resulted in 100% inactivation of Brucella, such that viable bacterial cells were not detected even at an ultrahigh concentration of 1010 colony-forming units/mL. Furthermore, A19BG had a typical BG morphology and good genetic stability. Moreover, it did not induce adverse reactions in guinea pigs.
The levels of antibodies, interferon-γ, interleukin-4, and CD4+ T cells in guinea pigs inoculated with the A19BG vaccine were similar to those inoculated with the existing A19 vaccine. Immunization with A19BG conferred a similar level of protection with that of A19 against Brucella melitensis M28 in both guinea pigs and cattle. In conclusion, the combination of biological lysis and H2O2-mediated inactivation is a safe and effective strategy that can serve as a reference for the preparation of BG vaccines.

Infection and protection responses of deletion mutants of non-structural proteins of foot-and-mouth disease virus serotype Asia1 in guinea pigs

The development of a negative marker vaccine against the foot-and-mouth disease virus (FMDV) will enhance the capabilities to differentiate vaccinated from infected animals and move forward in the progressive control pathway for the control of FMD. Here, we report the development of mutant FMDV of Asia1 with partial deletion of non-structural proteins 3A and 3B and characterization of their infectivity and protection response in the guinea pig model. The deleted FMDV Asia1/IND/63/1972 mutants, pAsiaΔ3A and pAsiaΔ3A3B1 were constructed from the full-length infectious clone pAsiaWT, the viable virus was rescued, and the genetic stability of the mutants was confirmed by 20 monolayer passages in BHK21 cells.
The mutant Asia1 viruses showed comparable growth pattern and infectivity with that of AsiaWT in the cell culture. However, the AsiaΔ3A3B1 virus showed smaller plaque and lower virus titer with reduced infectivity in the suckling mice. In guinea pigs, the AsiaΔ3A3B1 virus failed to induce the disease, whereas the AsiaΔ3A virus induced typical secondary lesions of FMD. Vaccination with inactivated Asia1 mutant viruses induced neutralizing antibody response that was significantly lower than that of the parent virus on day 28 post-vaccination (dpv) in guinea pigs (P < 0.05).
Furthermore, challenging the vaccinated guinea pigs with the homologous vaccine strain of FMDV Asia1 conferred complete protection. It is concluded that the mutant AsiaΔ3A3B1 virus has the potential to replace the wild-type virus for use as a negative marker vaccine after assessing the vaccine worth attributes in suspension cell and protective efficacy study in cattle.Key points• Deletion mutant viruses of FMDV Asia1, developed by PCR-mediated mutagenesis of NSP 3A and 3B1, were genetically stable.• The growth kinetics and antigenic relatedness of the mutant viruses were comparable with that of the wild-type virus.• Vaccination of guinea pigs with the deletion mutant viruses conferred complete protection upon challenge with the homologous virus.

Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies

Guinea pigs exposed to multiple infestations with Ixodes scapularis ticks develop acquired resistance to ticks, which is also known as tick immunity. The I. scapularis salivary components that contribute to tick immunity are likely multifactorial. An anticoagulant that inhibits factor Xa, named Salp14, is present in tick saliva and is associated with partial tick immunity. A tick bite naturally releases tick saliva proteins into the vertebrate host for several days, which suggests that the mode of antigen delivery may influence the genesis of tick immunity. We therefore utilized Salp14 as a model antigen to examine tick immunity using mRNA lipid nanoparticles (LNPs), plasmid DNA, or recombinant protein platforms.
salp14 containing mRNA-LNPs vaccination elicited erythema at the tick bite site after tick challenge that occurred earlier, and that was more pronounced, compared with DNA or protein immunizations. Humoral and cellular responses associated with tick immunity were directed towards a 25 amino acid region of Salp14 at the carboxy terminus of the protein, as determined by antibody responses and skin-testing assays.
This study demonstrates that the model of antigen delivery, also known as the vaccine platform, can influence the genesis of tick immunity in guinea pigs. mRNA-LNPs may be useful in helping to elicit erythema at the tick bite site, one of the most important early hallmarks of acquired tick resistance. mRNA-LNPs containing tick genes is a useful platform for the development of vaccines that can potentially prevent selected tick-borne diseases.

Characterization of Canine Influenza Virus A (H3N2) Circulating in Dogs in China from 2016 to 2018

Avian H3N2 influenza virus follows cross-host transmission and has spread among dogs in Asia since 2005. After 2015-2016, a new H3N2 subtype canine influenza epidemic occurred in dogs in North America and Asia. The disease prevalence was assessed by virological and serological surveillance in dogs in China.
Herein, five H3N2 canine influenza virus (CIV) strains were isolated from 1185 Chinese canine respiratory disease samples in 2017-2018; these strains were on the evolutionary branch of the North American CIVs after 2016 and genetically far from the classical canine H3N2 strain discovered in China before 2016. Serological surveillance showed an HI antibody positive rate of 6.68%. H3N2 was prevalent in the coastal areas and northeastern regions of China. In 2018, it became the primary epidemic strain in the country.
The QK01 strain of H3N2 showed high efficiency in transmission among dogs through respiratory droplets. Nevertheless, the virus only replicated in the upper respiratory tract and exhibited low pathogenicity in mice. Furthermore, highly efficient transmission by direct contact other than respiratory droplet transmission was found in a guinea pig model.
The low-level replication in avian species other than ducks could not facilitate contact and airborne transmission in chickens. The current results indicated that a novel H3N2 virus has become a predominant epidemic strain in dogs in China since 2016 and acquired highly efficient transmissibility but could not be replicated in avian species. Thus, further monitoring is required for designing optimal immunoprophylactic tools for dogs and estimating the zoonotic risk of CIV in China.

Hemoglobin antibody
1 mg 217.2 EUR

Hemoglobin antibody
1 mg 177.6 EUR

Hemoglobin antibody
1 mg 217.2 EUR

Hemoglobin antibody
250 ug 376.8 EUR

Hemoglobin antibody
250 ug 376.8 EUR

Hemoglobin antibody
1 mg 418.8 EUR

Hemoglobin antibody
1 mg 418.8 EUR

Hemoglobin antibody
500 ug 591.6 EUR

Hemoglobin antibody
1 mg 277.2 EUR

Hemoglobin antibody
1 mg 277.2 EUR
Uncategorized

Focus Simplexa NATtrol

They represent the preferred industry standard for molecular diagnostic testing and can be used as independent (third party) quality control materials. NATtrol products are prepared from purified microorganisms that are grown in cell culture, in microbial culture, or isolated from the plasma of infected individuals.

NATtrol treatment modifies surface proteins and makes organisms non-infectious and stable in the refrigerator while retaining the complete genome. Inactivation of the organisms is verified by the absence of growth invalidated infectivity tests based on tissue cultures or in validated growth protocols (as appropriate)

  • Non-infectious and stable in the refrigerator
  • Purified and intact organisms
  • Comprehensive process controls to monitor extraction and amplification steps
  • Available in different formats (one or more analytes)
  • Can be used on various molecular assay platforms and analyzes
  • Traceable to WHO international standards (if applicable)
  • Shelf life of 12 to 24 months
  • Extensive coverage of patents * and/or pending patents

Frequent use of NATtrol controls can be used to:

  • Train and supervise laboratory staff
  • Assess lot-to-lot consistency of test kits and test reagents
  • Monitor daily variations in reported results
  • Provide an impartial and independent assessment of the competence of the tests
  • Provide consistent, reliable, and accurate quality control solutions
  • Help identify lab trends
Uncategorized

3 COMMON PROBLEMS WHEN DOING AN ELISA

The ELISA immunoassays are among the most versatile to detect, identify and / or quantitate a particular antigen present in our sample. It is a highly sensitive, robust and relatively inexpensive test, quick and easy to carry out.

But despite the apparent simplicity of its protocol, as with most biological assays, there are times when the results are not as expected.

In this post we will focus on  3 common problems when doing an ELISA , and we will try to give some guidelines to be able to  solve them successfully .

Some of the common problems when doing an ELISA are obtaining a weak , low intensity or even non-existent signal , generating a high background noise that distorts the results, or the high inconsistency of the results between wells .

Next we leave you a list of Possible Causes (PC) and Solutions (S) for these 3 common problems when doing an ELISA.

1.- THE SIGNAL INTENSITY IS VERY LOW OR NON-EXISTENT:

PC: Problems with the protocol

S: The essay may not have been prepared correctly, and to fix it it is necessary to review several points:

  • Check that each step of the protocol has been applied correctly
  • Check that the wavelength and filters used in the plate reader are appropriate. For this, the test can be repeated using a positive control.

PC: Antibody problems

S: Antibodies are the most critical reagents in ELISA tests, and it is important to pay attention to the following points:

  • Use the dilution recommended by the manufacturer, or failing that, optimize the dilution of the antibody to be used.
  • Make sure you use enough antibodies, testing different concentrations of the antibodies to identify the optimal concentration for your assay.
  • Make sure that the antibodies have been stored correctly and have not undergone excessive freeze / thaw cycles .

PC: Problems with antigen

S: When the plates are covered with the antigen and when adding the primary antibody the signal is weak or null, there are two main aspects to check:

  • Sometimes it is possible that a sufficient amount of antigen has not adhered to the plate, try adding more.
  • In the case of peptide antigens, they must be previously conjugated to a large carrier protein in order to facilitate the recognition of the epitope by the antibody.

PC: Problems with reagents

S: Always make sure that:

  • The reagents are at room temperature before starting the assay
  • Check expiration dates
  • Check that they have been prepared correctly and have been added in the corresponding order.
  • Make sure that they do not interfere with other buffers or compounds present in the sample such as sodium acid, EDTA, etc.
  • Avoid mixing reagents from different kits.

PC: Low incubation times and temperature

S: Be sure to incubate the samples for the time specified by the manufacturer and optimize the incubation temperature for your assay. Remember that the reagents must be at room temperature before starting the assay.

PC: Storage conditions

S: Stores reagents to your specifications, keeping in mind that all reagents may not need the same storage requirements.

2.- THE BACKGROUND NOISE IS VERY HIGH

PC: Antibody problems

S: Regarding antibodies, there can be several cases:

  • That the concentration of antibody used is too high. This will be resolved by reducing its concentration, or by carrying out an optimization test to determine the ideal concentration.
  • There are cross reactivity problems, for which a negative control should be used.
  • Non-specific binding where the antibody is detecting other molecules besides the target antigen. The solution is through the use of affinity purified antibodies and the use of the appropriate blocking buffers .

PC: Problems with reagents

S: Regarding the different reagents, we must make sure that:

  • The stop solution is added to avoid an over development of the reaction.
  • The detection reagent has been properly diluted, and if so, retest with an even higher dilution.
  • The appropriate blocking buffers have been used and the blocking time has been sufficient.

PC: Incubation problems

S: In case of obtaining high background noise, it may be necessary to reduce the incubation temperature. On the other hand, it is necessary to ensure that the incubation of the substrate is carried out in dark conditions.

PC: Insufficient washes

S: Carefully wash the bottom of the plate and repeat the reading.

3.- THE VARIATION OF RESULTS BETWEEN WELLS IS VERY HIGH

PC: Inadequate incubation

S: Regarding the incubation step, it is important:

  • Do not stack the plates during the process to ensure that the temperature is evenly distributed.
  • Make sure there are no bubbles inside the wells before incubation.

PC: improper washing

S: Make sure to thoroughly wash all wells, as inhomogeneous washing could result in a high coefficient of variation.

 

 

Uncategorized

How To Improve Protein Quality

When working with protein samples , there are critical factors that must be closely monitored to avoid their degradation or dysfunction and guarantee the reliability of the results.

These factors therefore reflect the quality of the proteins and can be basically summarized as:

  • Integrity
  • Purity
  • Homogeneity
  • Solubility
  • Stability
  • Storage

In this post we bring you some tips to improve the quality of proteins and thus optimize the results of the tests.

1.- OPTIMIZATION OF PROTEIN PURITY AND INTEGRITY

Optimizing the purity and integrity of proteins involves avoiding or minimizing contamination of the sample with impurities, modified proteins or degradation products, among others.

Some of the steps that can be taken to this end are:

  1. Change the purification protocol by modifying for example the washing and elution conditions or adding additional purification steps such as ion exchange chromatography.
  2. Modify the conditions of induction of protein expression
  3. Use a different cloning vector
  4. Use a different expression system

2.- OPTIMIZATION OF PROTEIN HOMOGENEITY AND SOLUBILITY

To prevent or eliminate the formation of aggregates and increase the solubility of the protein s interest, there are several points that can affect, such as:

  1. Always perform size exclusion chromatography as the last step in the protein purification process.
  2. Do not over-concentrate the sample, since the processes applied for this purpose usually induce the aggregation of proteins (Remember this entry about 5 techniques to concentrate proteins ).
  3. Modify the composition of the buffer in which the protein is located until optimizing the pH, salinity, additives, etc. best suited in each case.

3.- OPTIMIZATION OF THE STABILITY AND STORAGE OF PROTEINS

Regarding the stability and medium or long-term storage of proteins, it is common to think that freezing and cryopreservation is the ideal method. And although this is true in a large part of the cases, it is not always the case due to the intrinsic variability of each individual protein.

That is why it is advisable to study the stability of each protein of interest to identify the optimal storage method in each case, whether it be simple refrigeration, freezing, lyophilization, etc.

You can expand the information in this post on How to store proteins to avoid their degradation .

 

 

A novel isolator-based system promotes viability of human embryos during laboratory processing.
A novel isolator-based system promotes viability of human embryos during laboratory processing.

A novel isolator-based system promotes viability of human embryos during laboratory processing.

In vitro fertilisation (IVF) and associated applied sciences are arguably essentially the most difficult of all cell tradition purposes. The beginning materials is a single cell from which one goals to supply an embryo succesful of establishing a being pregnant ultimately resulting in a dwell beginning.

Laboratory processing during IVF remedy requires open manipulations of gametes and embryos, which usually entails publicity to ambient situations.

To scale back the danger of mobile stress, we’ve got developed a very enclosed system of interlinked isolator-based workstations designed to keep up oocytes and embryos in a physiological setting all through the IVF course of. Comparison of scientific and laboratory information earlier than and after the introduction of the brand new system revealed that considerably extra embryos developed to the blastocyst stage within the enclosed isolator-based system in contrast with standard open-fronted laminar circulate hoods.

Moreover, blastocysts produced within the isolator-based system contained considerably extra cells and their growth was accelerated. Consistent with this, the introduction of the enclosed system was accompanied by a major enhance within the scientific being pregnant fee and within the proportion of embryos implanting following switch to the uterus.

alpha Tubulin (alpha Tubulin) Antibody
abx230332-100ug 100 ug
EUR 610.8

alpha Tubulin (alpha Tubulin) Antibody
abx230333-100ug 100 ug
EUR 610.8

alpha Tubulin (alpha Tubulin) Antibody
abx230334-100ug 100 ug
EUR 610.8

alpha Tubulin (alpha Tubulin) Antibody
abx230335-100ug 100 ug
EUR 610.8

alpha Tubulin (alpha tubulin) Antibody
20-abx133573
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

alpha Tubulin (alpha Tubulin) Antibody
abx448544-100ug 100 ug
EUR 627.6

alpha Tubulin (alpha Tubulin) Antibody
abx019012-100ug 100 ug
EUR 385.2

alpha Tubulin (alpha Tubulin) Antibody
abx005570-50ul 50 ul
EUR 326.4

alpha Tubulin (alpha Tubulin) Antibody
20-abx005573
  • EUR 427.20
  • EUR 594.00
  • EUR 326.40
  • 100 ul
  • 200 ul
  • 50 ul

alpha Tubulin (alpha Tubulin) Antibody (ALP)
abx446849-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (APC)
abx446850-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (HRP)
abx446853-100ug 100 ug
EUR 678

alpha Tubulin (alpha Tubulin) Antibody (RPE)
abx446856-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (FITC)
abx446852-100ug 100 ug
EUR 678

alpha Tubulin (alpha Tubulin) Antibody (PerCP)
abx446855-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (Biotin)
abx446851-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (Streptavidin)
abx446857-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 390)
abx446841-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 488)
abx446842-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 565)
abx446843-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 594)
abx446844-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 633)
abx446845-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 655)
abx446846-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 680)
abx446847-100ug 100 ug
EUR 693.6

alpha Tubulin (alpha Tubulin) Antibody (ATTO 700)
abx446848-100ug 100 ug
EUR 693.6

Alpha Tubulin
E8RE6006 100ul
EUR 275
Description: Available in various conjugation types.

alpha Tubulin (alpha Tubulin) Antibody (PE/ATTO 594)
abx446854-100ug 100 ug
EUR 710.4

alpha Tubulin 4A
E8ET1705-31 100ul
EUR 275
Description: Available in various conjugation types.

Rabbit anti Arabidopsis thaliana Tubulin alpha-1 chain (TUBA1) IgG affinity pure, loading control for WB
TUBA111-A 100 ug
EUR 548.4

alpha Tubulin antibody
10C-CR2063M1 100 ul
EUR 159.6
Description: Mouse monoclonal alpha Tubulin antibody

alpha Tubulin antibody
10R-6523 100 ug
EUR 418.8
Description: Mouse monoclonal alpha Tubulin antibody

alpha Tubulin antibody
10R-7916 100 ug
EUR 386.4
Description: Mouse monoclonal alpha Tubulin antibody

alpha Tubulin antibody
10R-8421 100 ul
EUR 471.6
Description: Mouse monoclonal alpha Tubulin antibody

alpha Tubulin antibody
10R-T130a 100 ug
EUR 663.6
Description: Mouse monoclonal alpha Tubulin antibody

alpha Tubulin antibody
20R-2948 100 ul
EUR 471.6
Description: Rabbit polyclonal alpha Tubulin antibody

alpha Tubulin antibody
22038-100ul 100ul
EUR 468

alpha Tubulin antibody
70R-13229 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal alpha Tubulin antibody

Alpha Tubulin Antibody
R30095 100 ug
EUR 356.15
Description: Alpha-tubulin (b-alpha-1) mRNA is expressed at a molecular weight of about 50-55,000D. The 3-prime UTR of the protein is more than 80% homologous to the UTR of the rat brain alpha-tubulin gene IL-alpha-T1. Alpha tubulin is a predicted 451-amino acid protein that is 100% identical to the rat homolog and differs by only 2 and 3 amino acids from the pig and chicken homologs, respectively.

alpha Tubulin Antibody
AF4651-100ul 100ul
EUR 350

alpha Tubulin Antibody
AF4651-200ul 200ul
EUR 450

alpha Tubulin Antibody
AF4651-50ul 50ul
EUR 250

alpha Tubulin Antibody
AF4651 100ul
EUR 350
Description: Human,Mouse,Rat

alpha Tubulin Antibody
E11-184651 100ug/100ul
EUR 225
Description: Available in various conjugation types.

alpha Tubulin antibody
E39-00333 100ug/100ul
EUR 225
Description: Available in various conjugation types.

alpha Tubulin antibody
CAF50026-100ug 100ug
EUR 338

Tubulin alpha antibody
70R-30819 100 ug
EUR 392.4
Description: Rabbit polyclonal Tubulin alpha antibody

Tubulin alpha Antibody
ABF0524 100 ug
EUR 525.6

Tubulin alpha Antibody
ABF7010 100 ug
EUR 525.6

Tubulin alpha Antibody
20-abx013239
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Tubulin alpha Antibody
AF0524-100ul 100ul
EUR 280

Tubulin alpha Antibody
AF0524-200ul 200ul
EUR 350

Tubulin alpha Antibody
T0033 100ul
EUR 250
Description: Human,Mouse,Zebrafish,Rabbit

Tubulin alpha Antibody
AF7010-100ul 100ul
EUR 250

Tubulin alpha Antibody
AF7010-1ml 1ml
EUR 1200

Tubulin alpha Antibody
AF7010-200ul 200ul
EUR 350

Tubulin alpha Antibody
AF7010-50ul 50ul
EUR 150

Tubulin alpha Antibody
AF7010 100ul
EUR 250
Description: Human,Mouse,Rat,Pig,Bovine,Rabbit,Chicken,Plants,Fish

Tubulin alpha Antibody
AF0524 100ul
EUR 280
Description: Human,Mouse,Rat

Tubulin alpha Antibody
T0033-100ul 100ul
EUR 250

Tubulin alpha Antibody
T0033-1ml 1ml
EUR 1200

Tubulin alpha Antibody
T0033-200ul 200ul
EUR 350

Tubulin alpha Antibody
T0033-50ul 50ul
EUR 150

Tubulin alpha Antibody
E18-0524-1 50μg/50μl
EUR 145
Description: Available in various conjugation types.

Tubulin alpha Antibody
E18-0524-2 100μg/100μl
EUR 225
Description: Available in various conjugation types.

Tubulin alpha Antibody
E18-7010-1 50μg/50μl
EUR 145
Description: Available in various conjugation types.

Tubulin alpha Antibody
E18-7010-2 100μg/100μl
EUR 225
Description: Available in various conjugation types.

alpha Tubulin Mouse mAb
AC012 50 ul
EUR 234

alpha Tubulin Rabbit mAb
AC013 50 ul
EUR 318

alpha Tubulin Rabbit pAb
AC024 50 ul
EUR 267.6

alpha Tubulin Rabbit pAb
AC025 50 ul
EUR 267.6

alpha Tubulin Rabbit pAb
E2619725 100ul
EUR 225
Description: Available in various conjugation types.

alpha Tubulin Rabbit pAb
E2540004 100ul
EUR 225
Description: Available in various conjugation types.

alpha Tubulin Rabbit pAb
E2380636 100ul
EUR 225
Description: Available in various conjugation types.

alpha Tubulin Rabbit pAb
E2380637 100ul
EUR 225
Description: Available in various conjugation types.

alpha Tubulin Rabbit mAb
E2R23452 100μl
EUR 225
Description: Available in various conjugation types.

alpha Tubulin Rabbit mAb
E2R23453 100ul
EUR 255
Description: Available in various conjugation types.

alpha Tubulin Rabbit mAb
E2R23454 100ul
EUR 255
Description: Available in various conjugation types.

alpha Tubulin 4A Antibody
abx148144-100ug 100 ug
EUR 526.8

alpha Tubulin 4a antibody
22537-100ul 100ul
EUR 468

alpha Tubulin 4A antibody
70R-2911 50 ug
EUR 560.4
Description: Rabbit polyclonal alpha Tubulin 4A antibody raised against the middle region of TUBA4A

alpha Tubulin 4A Antibody
49624-100ul 100ul
EUR 399.6

alpha Tubulin 4A Antibody
49624-50ul 50ul
EUR 286.8

alpha Tubulin 1A antibody
70R-13312 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal alpha Tubulin 1A antibody

alpha Tubulin 4a antibody
70R-13517 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal alpha Tubulin 4a antibody

alpha Tubulin 1A antibody
70R-13631 100 ul
EUR 548.4
Description: Affinity purified Rabbit polyclonal alpha Tubulin 1A antibody

alpha Tubulin 3C antibody
70R-2123 50 ug
EUR 560.4
Description: Rabbit polyclonal alpha Tubulin 3C antibody raised against the N terminal of TUBA3C

alpha Tubulin 3C antibody
70R-2135 50 ug
EUR 560.4
Description: Rabbit polyclonal alpha Tubulin 3C antibody raised against the N terminal of TUBA3C

alpha Tubulin 4A antibody
70R-2151 50 ug
EUR 560.4
Description: Rabbit polyclonal alpha Tubulin 4A antibody raised against the middle region of TUBA4A

alpha Tubulin 4A Antibody
ABD2901 100 ug
EUR 525.6

alpha Tubulin 4A Antibody
DF2901 200ul
EUR 420

alpha Tubulin 4A Antibody
E19-2901-1 50ug/50ul
EUR 145
Description: Available in various conjugation types.

alpha Tubulin 4A Antibody
E19-2901-2 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Alpha Tubulin Antibody / TUB1
RQ5287 100ul
EUR 356.15
Description: Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. [UniProt]

Alpha Tubulin Antibody / TUBA
V8404-100UG 100 ug
EUR 349.3
Description: Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulin. This MAb recognizes an epitope of alpha-tubulin. The alpha-tubulin is globular protein that exists in cells as part of soluble alpha/beta-tubulin dimer or it is polymerized into microtubules. In different species it is coded by multiple tubulin genes that form tubulin classes (in human 6 genes). Expressed tubulin genes are named tubulin isotypes. Some of the tubulin isotypes are expressed ubiquitously, while some have more restricted tissue expression. Alpha-tubulin is also subject of numerous post-translational modifications. Tubulin isotypes and their posttranslational modifications are responsible for multiple tubulin charge variants - tubulin isoforms. Heterogeneity of alpha-tubulin is concentrated in C-terminal structural domain

Alpha Tubulin Antibody / TUBA
V8404-20UG 20 ug
EUR 153.3
Description: Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulin. This MAb recognizes an epitope of alpha-tubulin. The alpha-tubulin is globular protein that exists in cells as part of soluble alpha/beta-tubulin dimer or it is polymerized into microtubules. In different species it is coded by multiple tubulin genes that form tubulin classes (in human 6 genes). Expressed tubulin genes are named tubulin isotypes. Some of the tubulin isotypes are expressed ubiquitously, while some have more restricted tissue expression. Alpha-tubulin is also subject of numerous post-translational modifications. Tubulin isotypes and their posttranslational modifications are responsible for multiple tubulin charge variants - tubulin isoforms. Heterogeneity of alpha-tubulin is concentrated in C-terminal structural domain

Alpha Tubulin Antibody / TUBA
V8404SAF-100UG 100 ug
EUR 349.3
Description: Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulin. This MAb recognizes an epitope of alpha-tubulin. The alpha-tubulin is globular protein that exists in cells as part of soluble alpha/beta-tubulin dimer or it is polymerized into microtubules. In different species it is coded by multiple tubulin genes that form tubulin classes (in human 6 genes). Expressed tubulin genes are named tubulin isotypes. Some of the tubulin isotypes are expressed ubiquitously, while some have more restricted tissue expression. Alpha-tubulin is also subject of numerous post-translational modifications. Tubulin isotypes and their posttranslational modifications are responsible for multiple tubulin charge variants - tubulin isoforms. Heterogeneity of alpha-tubulin is concentrated in C-terminal structural domain

anti- alpha Tubulin antibody
FNab00332 100µg
EUR 658.5
Description: Antibody raised against alpha Tubulin

anti- alpha Tubulin antibody
FNab00333 100µg
EUR 658.5
Description: Antibody raised against alpha Tubulin

anti- alpha Tubulin antibody
FNab00334 100µg
EUR 658.5
Description: Antibody raised against alpha Tubulin

anti- alpha Tubulin antibody
FNab00335 100µg
EUR 658.5
Description: Antibody raised against alpha Tubulin

Alpha Tubulin Antibody / TUBA1B
R20196-0.1ML 100ul
EUR 347.65
Description: This recombinant Alpha Tubulin antibody reacts to a-Tubulin, including Tubulin alpha-1A chain and Tubulin alpha-1B chain.

Alpha Tubulin Antibody / TUBA1B
R20196BTN-50UL 50ul
EUR 347.65
Description: This recombinant Alpha Tubulin antibody reacts to a-Tubulin (1A & 1B).

Alpha Tubulin Antibody / TUBA1A
RQ5776 100 ug
EUR 356.15
Description: Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulins. The genes encoding these microtubule constituents belong to the tubulin superfamily, which is composed of six distinct families. Genes from the alpha, beta and gamma tubulin families are found in all eukaryotes. The alpha and beta tubulins represent the major components of microtubules, while gamma tubulin plays a critical role in the nucleation of microtubule assembly. There are multiple alpha and beta tubulin genes, which are highly conserved among species. This gene encodes alpha tubulin and is highly similar to the mouse and rat Tuba1 genes. Northern blot studies have shown that the gene expression is predominantly found in morphologically differentiated neurologic cells. This gene is one of three alpha-tubulin genes in a cluster on chromosome 12q. Mutations in this gene cause lissencephaly type 3 (LIS3) - a neurological condition characterized by microcephaly, intellectual disability, and early-onset epilepsy caused by defective neuronal migration. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

alpha tubulin (AcK40) Antibody
20-abx134685
  • EUR 460.80
  • EUR 727.20
  • EUR 276.00
  • 100 ul
  • 200 ul
  • 30 ul

alpha Tubulin antibody (biotin)
61R-1585 100 ug
EUR 625.2
Description: Mouse monoclonal alpha Tubulin antibody (biotin)

Tubulin alpha-1B antibody
23103-100ul 100ul
EUR 468

alpha tubulin Blocking Peptide
20-abx061155
  • EUR 343.20
  • EUR 510.00
  • 1 mg
  • 5 mg

alpha Tubulin Blocking Peptide
AF4651-BP 1mg
EUR 234

Tubulin alpha 1A antibody
22015-100ul 100ul
EUR 468

Tubulin Alpha Antibody (HRP)
abx415529-01mg 0.1 mg
EUR 610.8

Polyclonal alpha Tubulin Antibody
APR11374G 0.1ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human alpha Tubulin . This antibody is tested and proven to work in the following applications:

alpha Tubulin ELISA KIT|Human
EF007730 96 Tests
EUR 826.8

alpha Tubulin（yeast） Rabbit pAb
E2380638 100ul
EUR 225
Description: Available in various conjugation types.

Tubulin, Alpha 8 (TUBA8) Antibody
20-abx116348
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Detyrosinated Alpha Tubulin Antibody
R20459-0.1ML 100ul
EUR 409

Tubulin alpha Blocking Peptide
AF0524-BP 1mg
EUR 234

Tubulin alpha Blocking Peptide
AF7010-BP 1mg
EUR 234

Tubulin Alpha 4A (TUBA4A) Antibody
20-abx317902
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Tubulin Alpha 1C (TUBA1C) Antibody
20-abx318293
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Tubulin Alpha 1C (TUBA1C) Antibody
abx246735-400ul 400 ul
EUR 627.6

Tubulin Alpha 1C (TUBA1C) Antibody
abx246735-80l 80 µl
EUR 343.2

Tubulin Alpha 1C (TUBA1C) Antibody
abx246736-400ul 400 ul
EUR 678

Tubulin Alpha 1C (TUBA1C) Antibody
abx246736-80l 80 µl
EUR 360

Tubulin Alpha 1C (TUBA1C) Antibody
20-abx241937
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Tubulin Alpha 1C (TUBA1C) Antibody
20-abx241938
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Tubulin Alpha 4A (TUBa4A) Antibody
20-abx178746
  • EUR 1479.60
  • EUR 710.40
  • 1 mg
  • 200 ug

Tubulin Alpha 4A (TUBa4A) Antibody
20-abx178747
  • EUR 1479.60
  • EUR 710.40
  • 1 mg
  • 200 ug

Tubulin, Alpha 1A (TUBA1A) Antibody
20-abx116344
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Tubulin, Alpha 1B (TUBA1B) Antibody
20-abx116345
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Tubulin, Alpha 1C (TUBA1C) Antibody
20-abx116346
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Tubulin, Alpha 4A (TUBA4A) Antibody
20-abx116347
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Tubulin Alpha 4A (TUBA4A) Antibody
abx147277-100ug 100 ug
EUR 526.8

Tubulin Alpha 4A (TUBA4A) Antibody
abx147278-100ug 100 ug
EUR 526.8

The information point out that safety from ambient situations promotes improved growth of human embryos. Importantly, we discovered that it was solely possible to conduct all IVF-related procedures within the isolator-based workstations.

A novel isolator-based system promotes viability of human embryos during laboratory processing.

A novel isolator-based system promotes viability of human embryos during laboratory processing.

A clinician’s private view of assisted reproductive know-how over 35 years.

This invited presentation is meant to cowl scientific developments within the evolution of assisted reproductive know-how (ART), a course of which was tried during the 1940’s and 50’s and culminated within the first fruition in 1978. The first in vitro fertilisation (IVF) youngster ensued following the partnership by a scientist with a focussed ambition (Nobel laureate Robert Edwards) becoming a member of with the gynaecologist who launched laparoscopy to Britain within the late 60’s (Patrick Steptoe).

My journey commenced in 1976 as a clinician who grew to become immersed within the embryological and endocrinological science, whence most progress in ART emanates, and continued right into a medical directorship place from which this private view is documented.

Several scientific advances have been essential developments within the understanding and administration of sub-fertile sufferers. However evolution of the assorted laboratory sciences has been the foremost key important to assembly each the rapid in addition to the long-term wants for human replica.

The future requires a a lot better understanding and management over gametogenesis and a laboratory course of which way more carefully duplicates intrinsic reproductive physiology, avoiding gamete and embryo publicity to the ambiance.

This invited presentation is meant to cowl scientific developments within the evolution of assisted reproductive know-how (ART), a course of which was tried during the 1940’s and 50’s and culminated within the first fruition in 1978. The first in vitro fertilisation (IVF) youngster ensued following the partnership by a scientist with a focussed ambition (Nobel laureate Robert Edwards) becoming a member of with the gynaecologist who launched laparoscopy to Britain within the late 60’s (Patrick Steptoe).

My journey commenced in 1976 as a clinician who grew to become immersed within the embryological and endocrinological science, whence most progress in ART emanates, and continued right into a medical directorship place from which this private view is documented. Several scientific advances have been essential developments within the understanding and administration of sub-fertile sufferers.

However evolution of the assorted laboratory sciences has been the foremost key important to assembly each the rapid in addition to the long-term wants for human replica. The future requires a a lot better understanding and management over gametogenesis and a laboratory course of which way more carefully duplicates intrinsic reproductive physiology, avoiding gamete and embryo publicity to the ambiance.

On the fate of primordial germ cells injected into early mouse embryos.
On the fate of primordial germ cells injected into early mouse embryos.

On the fate of primordial germ cells injected into early mouse embryos.

Primordial germ cells (PGCs) are the founder cells of the germline. Via gametogenesis and fertilisation this lineage generates a brand new embryo in the subsequent technology. PGCs are additionally the cell of origin of multilineage teratocarcinomas.

In vitro, mouse PGCs can provide rise to embryonic germ (EG) cells – pluripotent stem cells that may contribute to main chimaeras when launched into pre-implantation embryos. Thus, PGCs can provide rise to pluripotent cells in the course of the developmental cycle, throughout teratocarcinogenesis and by in vitro tradition. However, there isn’t any proof that PGCs can differentiate instantly into somatic cell varieties.

Furthermore, it’s typically assumed that PGCs don’t contribute to chimaeras following injection into the early mouse embryo. However, these knowledge have by no means been formally revealed. Here, we current the main knowledge from the unique PGC-injection experiments carried out 40 years in the past, alongside outcomes from newer research in three separate laboratories.

These outcomes have knowledgeable and influenced present fashions of the relationship between pluripotency and the germline cycle. Current applied sciences enable additional experiments to substantiate and develop upon these findings and permit definitive conclusions as to the developmental efficiency of PGCs.

On the fate of primordial germ cells injected into early mouse embryos.

On the fate of primordial germ cells injected into early mouse embryos.

MC Chang–Reproductive biologist of distinction 1908-1991.

This article evaluations the outstanding life and main scientific achievements of the reproductive biologist M.C. Chang. His scholarly profession progressed from college in Peking, through Edinburgh, Scotland, and Cambridge, England, to the newly based Worcester Foundation for Experimental Biology in Massachusetts. At every stage, the hand of fate is famous as are the help and encouragement of key professors.

Chang’s personal contributions on capacitation of spermatozoa, in vitro fertilisation of mammalian eggs, and transplantation of oocytes and embryos are all introduced out, as is his important enter to the creation and improvement of a steroid contraceptive capsule.

TCR alpha / beta Antibody
abx140255-01mg 0.1 mg
EUR 376.8

alpha beta TcR antibody (biotin)
61R-1695 100 ug
EUR 379.2
Description: Mouse monoclonal alpha beta TcR antibody (biotin)

TCR alpha / beta Antibody (PE)
abx139897-100tests 100 tests
EUR 577.2

TCR alpha / beta Antibody (PE)
abx140308-01mg 0.1 mg
EUR 510

TCR alpha / beta Antibody (APC)
abx139898-100tests 100 tests
EUR 577.2

TCR alpha / beta Antibody (FITC)
abx139900-100tests 100 tests
EUR 510

TCR alpha / beta Antibody (FITC)
abx140307-01mg 0.1 mg
EUR 477.6

TCR alpha / beta Antibody (PerCP)
abx139896-100tests 100 tests
EUR 577.2

TCR alpha / beta Antibody (Biotin)
abx139899-01mg 0.1 mg
EUR 510

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody
abx414734-05mg 0.5 mg
EUR 994.8

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody
abx414736-025mg 0.25 mg
EUR 678

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody
abx414737-01mg 0.1 mg
EUR 526.8

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody
abx413042-025mg 0.25 mg
EUR 678

Anti-Hu TCR alpha/beta PE
1P-607-T025 25 tests
EUR 168

Anti-Hu TCR alpha/beta PE
1P-607-T100 100 tests
EUR 288

Anti-Rt TCR alpha/beta PE
1P-653-C025 0.025 mg
EUR 146.4

Anti-Rt TCR alpha/beta PE
1P-653-C100 0.1 mg
EUR 244.8

Anti-Hu TCR alpha/beta APC
1A-607-T025 25 tests
EUR 168

Anti-Hu TCR alpha/beta APC
1A-607-T100 100 tests
EUR 288

Anti-Hu TCR alpha/beta FITC
1F-607-T025 25 tests
EUR 146.4

Anti-Hu TCR alpha/beta FITC
1F-607-T100 100 tests
EUR 244.8

Anti-Rt TCR alpha/beta FITC
1F-653-C025 0.025 mg
EUR 135.6

Anti-Rt TCR alpha/beta FITC
1F-653-C100 0.1 mg
EUR 223.2

Anti-Hu TCR alpha/beta PerCP
PC-607-T025 25 tests
EUR 168

Anti-Hu TCR alpha/beta PerCP
PC-607-T100 100 tests
EUR 288

Anti-Hu TCR alpha/beta Biotin
1B-607-C025 0.025 mg
EUR 146.4

Anti-Hu TCR alpha/beta Biotin
1B-607-C100 0.1 mg
EUR 244.8

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody (FITC)
abx414735-01mg 0.1 mg
EUR 610.8

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody (FITC)
abx413043-01mg 0.1 mg
EUR 610.8

T-Cell Receptor Alpha Beta (TCR Alpha/Beta) Antibody (FITC)
abx413044-05mg 0.5 mg
EUR 861.6

Anti-Hu TCR alpha/beta Purified
11-607-C025 0.025 mg
EUR 118.8

Anti-Hu TCR alpha/beta Purified
11-607-C100 0.1 mg
EUR 189.6

Anti-Rt TCR alpha/beta Purified
11-653-C100 0.1 mg
EUR 157.2

T-Cell Receptor Alpha Beta V Beta 1 (TCR Alpha/Beta Vb1) Antibody
abx415177-025mg 0.25 mg
EUR 710.4

T-Cell Receptor Alpha Beta V Beta 2 (TCR Alpha/Beta Vb2) Antibody
abx415178-025mg 0.25 mg
EUR 710.4

Rabbit Anti-Human p73 alpha/beta antiserum # 1
P73A11-S 100 ul
EUR 548.4

Human p73 alpha/beta Control/blocking peptide #1
P73A11-P 100 ug
EUR 196.8

Alpha V Beta 5 Integrin, Peptide Aptamer, unlabeled
AP-301-U 5 mg Ask for price

Actin (Pan, alpha, beta, gamma) Control/blocking peptide
ACTB22-P 100 ug
EUR 196.8

Alpha V Beta 5 Integrin, Peptide Aptamer, Biotinylated
AP-301-B 1 mg Ask for price

Rabbit Anti-Human p73 alpha/beta IgG # 1, aff pure
P73A11-A 100 ug
EUR 578.4

Alpha V Beta 5 Integrin, Peptide Aptamer, FITC labelled
AP-301-F 1 mg Ask for price

Rabbit Anti-Actin (Pan, alpha, beta, gamma) IgG, aff pure
ACTB22-A 100 ug
EUR 578.4

Mouse Monoclonal Anti-Actin (Pan, alpha, beta, gamma)-biotinylated
ACTB24-BTN 50 ul
EUR 489.6

Mouse Monoclonal Anti-Actin (Pan, alpha, beta, gamma) IgG, aff pure
ACTB24-M 100 ug
EUR 578.4

Monoclonal Anti-Human/mouse/rat HSP90 alpha/beta IgG, aff pure
HSP901-M 100 ul
EUR 578.4

Mouse Monoclonal Anti-Actin (Pan, alpha, beta, gamma) IgG-Cy3 conjugate
ACTB24-Cy3 100 ul
EUR 489.6

Mouse Monoclonal Anti-Actin (Pan, alpha, beta, gamma) IgG-FITC conjugate
ACTB24-FITC 100 ul
EUR 489.6

Endothelial intergerin Alpha-V Beta-3 (Clone 17.16), RNA Aptamer, unlabeled
AR-287-U Custom Ask for price

Pig Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500720-1 100 ul
EUR 854.4

Dog Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500760-1 100 ul
EUR 854.4

Mouse Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500710-1 100 ul
EUR 854.4

TCR alpha antibody
20R-1837 100 ug
EUR 807.6
Description: Rabbit polyclonal TCR alpha antibody

TCR alpha Antibody
5648-100 each
EUR 424.8

TCR alpha Antibody
5648-30T each
EUR 175.2

TCR alpha antibody
70R-12400 100 ug
EUR 552
Description: Rabbit polyclonal TCR alpha antibody

Rabbit Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500700-1 100 ul
EUR 854.4

Chicken Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500750-1 100 ul
EUR 854.4

Goat/Sheep Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500730-1 100 ul
EUR 854.4

Cow/Bovine Anti-C. perfringens toxins (Alpha+beta+Epsilon) Antibody ELISA, 96 tests, Quantitative
RB-500740-1 100 ul
EUR 854.4

TRAC Antibody / TCR alpha
RQ4617 100ug
EUR 356.15
Description: T cell receptors recognize foreign antigens which have been processed as small peptides and bound to major histocompatibility complex (MHC) molecules at the surface of antigen presenting cells (APC). Each T cell receptor is a dimer consisting of one alpha and one beta chain or one delta and one gamma chain. In a single cell, the T cell receptor loci are rearranged and expressed in the order delta, gamma, beta, and alpha. If both delta and gamma rearrangements produce functional chains, the cell expresses delta and gamma. If not, the cell proceeds to rearrange the beta and alpha loci. This region represents the germline organization of the T cell receptor alpha and delta loci. Both the alpha and delta loci include V (variable), J (joining), and C (constant) segments and the delta locus also includes diversity (D) segments. The delta locus is situated within the alpha locus, between the alpha V and J segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The alpha chain is synthesized by recombination joining a single V segment with a J segment. For both chains, the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. Five variable segments can be used in either alpha or delta chains and are described by TRAV/DV symbols. Several V and J segments of the alpha locus are known to be incapable of encoding a protein and are considered pseudogenes.

TCR beta Antibody
20-abx201040
  • EUR 326.40
  • EUR 493.20
  • 100 ug
  • 500 ug

TCR beta Antibody
20-abx218918
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

TCR beta antibody
10R-6585 100 ug
EUR 217.2
Description: Armenian Hamster monoclonal TCR beta antibody

TCR beta antibody
20R-1838 100 ug
EUR 807.6
Description: Rabbit polyclonal TCR beta antibody

TCR beta Antibody
5651-100 each
EUR 392.4

TCR beta Antibody
5651-30T each
EUR 175.2

TCR beta antibody
70R-12401 100 ug
EUR 501.6
Description: Rabbit polyclonal TCR beta antibody

TCR beta Antibody
DF8621 100ul
EUR 280
Description: Human

TCR beta Antibody
DF8621-100ul 100ul
EUR 280

TCR beta Antibody
DF8621-200ul 200ul
EUR 350

TCR alpha Blocking Peptide
5648BP-50 each
EUR 183.6

TCR alpha Blocking Peptide
33R-10580 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TCR alpha antibody, catalog no. 20R-1837

TCR alpha Blocking Peptide
33R-11053 50 ug
EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TCR alpha antibody, catalog no. 70R-12400

Mouse alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase-like (MGAT4D) Control/blocking peptide
AB-23037-P 100ug
EUR 196.8

Polyclonal TCR alpha Antibody
AMM08788G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TCR alpha . This antibody is tested and proven to work in the following applications:

Rabbit Anti-Mouse alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase-like (MGAT4D) IgG (aff pure)
AB-23037-A 100ug
EUR 578.4

Human Anti-Parietal cell (alpha and beta subunits of the Parietal Cell (H//K/ATPase) IgG ELISA kit, 96 tests, Quantitative
3300-315-PRG 1 kit
EUR 708

V alpha 24 J alpha 18 TCR antibody
10R-6544 100 ug
EUR 308.4
Description: Mouse monoclonal V alpha 24 J alpha 18 TCR antibody

TCR beta Antibody (PE)
20-abx201037
  • EUR 444.00
  • EUR 326.40
  • 100 ug
  • 25 ug

TCR beta antibody (PE)
61R-1386 100 ug
EUR 262.8
Description: Armenian Hamster monoclonal TCR beta antibody (PE)

TCR beta Antibody (APC)
20-abx201033
  • EUR 444.00
  • EUR 326.40
  • 100 ug
  • 25 ug

TCR beta Antibody (FITC)
20-abx201036
  • EUR 343.20
  • EUR 292.80
  • EUR 477.60
  • 100 ug
  • 25 ug
  • 500 ug

TCR beta antibody (FITC)
61R-1156 100 ug
EUR 217.2
Description: Armenian Hamster monoclonal TCR beta antibody (FITC)

TCR beta Antibody (PerCP)
20-abx201038
  • EUR 577.20
  • EUR 343.20
  • 100 ug
  • 25 ug

TCR beta Antibody (Biotin)
20-abx201034
  • EUR 376.80
  • EUR 309.60
  • 100 ug
  • 25 ug

TCR beta antibody (biotin)
61R-1632 100 ug
EUR 198
Description: Armenian Hamster monoclonal TCR beta antibody (biotin)

V alpha 2 TCR antibody (PE)
61R-1356 100 ug
EUR 379.2
Description: Rat monoclonal V alpha 2 TCR antibody (PE)

TCR beta Blocking Peptide
5651BP-50 each
EUR 183.6

TCR beta Blocking Peptide
33R-10581 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TCR beta antibody, catalog no. 20R-1838

TCR beta Blocking Peptide
33R-11054 50 ug
EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TCR beta antibody, catalog no. 70R-12401

TCR beta Blocking Peptide
DF8621-BP 1mg
EUR 234

V alpha 24 J alpha 18 TCR antibody (PE)
61R-1353 100 tests
EUR 664.8
Description: Mouse monoclonal V alpha 24 J alpha 18 TCR antibody (PE)

Recombinant (E.Coli) Human p38 alpha/SAPK2 alpha
RP-675 1 ug
EUR 343.2

V alpha 2 TCR antibody (FITC)
61R-1145 100 ug
EUR 340.8
Description: Rat monoclonal V alpha 2 TCR antibody (FITC)

Polyclonal TCR beta Antibody
APR00309G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TCR beta . This antibody is tested and proven to work in the following applications:

TCR Beta Polyclonal Antibody
ABP52577-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of TCR Beta from Human. This TCR Beta antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TCR ?

TCR Beta Polyclonal Antibody
ABP52577-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of TCR Beta from Human. This TCR Beta antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TCR ?

TCR Beta Polyclonal Antibody
ABP52577-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of TCR Beta from Human. This TCR Beta antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TCR ?

V alpha 2 TCR antibody (biotin)
61R-1598 100 ug
EUR 249.6
Description: Rat monoclonal V alpha 2 TCR antibody (biotin)

TCR beta antibody (allophycocyanin)
61R-1895 100 ug
EUR 418.8
Description: Armenian Hamster monoclonal TCR beta antibody (allophycocyanin)

TCR beta (V beta 5.3-related) Antibody
abx140251-01mg 0.1 mg
EUR 477.6

TCR beta (V beta 5.3-related) Antibody
abx140264-01mg 0.1 mg
EUR 477.6

human Topoisomerase II alpha (TOP2 alpha) Control/blocking peptide
TOP2A11-P 100 ug
EUR 196.8

V alpha 2 TCR antibody (allophycocyanin)
61R-1776 100 ug
EUR 573.6
Description: Rat monoclonal V alpha 2 TCR antibody (allophycocyanin)

TCR beta Antibody (CF-Blue)
20-abx201035
  • EUR 543.60
  • EUR 360.00
  • 100 ug
  • 25 ug

Anti-Ms TCR beta Purified
11-571-C100 0.1 mg
EUR 135.6

Recombinant purified, human Interleukin-1 alpha (IL-1 alpha), active
IL1A15-R-10 10 ug
EUR 416.4

anti-TCR alpha
YF-PA14966 50 ug
EUR 435.6
Description: Mouse polyclonal to TCR alpha

anti-TCR alpha
YF-PA14967 50 ul
EUR 435.6
Description: Mouse polyclonal to TCR alpha

Rabbit Anti-human Topoisomerase II alpha (TOP2 alpha) IgG, aff pure
TOP2A11-A 100 ug
EUR 578.4

V beta 13.2 TCR antibody (PE)
61R-1349 100 tests
EUR 522
Description: Mouse monoclonal V beta 13.2 TCR antibody (PE)

TCR beta Antibody (PerCP-Cy5.5)
20-abx201039
  • EUR 594.00
  • EUR 326.40
  • 100 ug
  • 25 ug

V beta 13.1 TCR antibody (FITC)
61R-1141 25 tests
EUR 282
Description: Mouse monoclonal V beta 13.1 TCR antibody (FITC)

Recombinant Human Alpha-Synuclein
RP-847 20 ug
EUR 196.8

PP2A alpha + beta
E8ET1611-54 100ul
EUR 275
Description: Available in various conjugation types.

PGC1 alpha+beta
E8ET1702-96 100ul
EUR 275
Description: Available in various conjugation types.

PP2A (alpha+beta)
E8M1603-4 100ul
EUR 275
Description: Available in various conjugation types.

PP2A (alpha+beta)
E8R1510-31 100ul
EUR 275
Description: Available in various conjugation types.

V beta 10b TCR antibody (PE)
61R-1352 100 ug
EUR 379.2
Description: Rat monoclonal V beta 10b TCR antibody (PE)

Alpha 2-Antiplasmin, Human Plasma
A2AP15-100 100 ug
EUR 196.8

Alpha 1-Antitrypsin, Human Plasma
A1AT15-N 1 mg
EUR 196.8

Spectrin (alpha + beta)
E8ER1917-09 100ul
EUR 275
Description: Available in various conjugation types.

Mouse alpha Macroglobulin protein, pure
AMGL15-N-25 25 ug
EUR 270

alpha+beta Synuclein
E8ET1609-66 100ul
EUR 275
Description: Available in various conjugation types.

Alpha 1-Antichymotrypsin , Human Plasma
A1CT15-N-100 100 ug
EUR 196.8

Rabbit Anti-Rat Glutathione Transferase alpha (GST-alpha) antiserum
GSTA11-S 100 ul
EUR 548.4

Monoclonal anti-human Alpha (FSH-Alpha), IgG clone 3 aff pure
FSHA12-M 1 mg
EUR 578.4

Rabbit Anti-Human Estrogen receptor alpha (ER-alpha) peptide IgG
ERA12-A 100 ug
EUR 578.4

Rabbit Anti-Human Glutathione Transferase alpha (GST-alpha) antiserum
GSTA12-S 100 ul
EUR 548.4

Human hypoxia-inducible transcription factor 1 alpha (HIF-1 alpha) ELISA Kit, 96 tests, Quantitative
100-530-HIF 1 Kit
EUR 854.4

Recombinant (E.Coli) Human Thyrostimulin Alpha
RP-595 10 ug
EUR 343.2

Goat Anti-Human Lutenizing Hormone Alpha (LH-Alpha) IgG aff pure
LHA13-A 1 mg
EUR 343.2

Alpha 2-HS Glycoprotein, Human Plasma
A2HG15-N 1 mg
EUR 343.2

Goat Anti-Ferret IgA (alpha), unlabeled
70519 0.5 mg
EUR 255.6

Rabbit Anti-Human alpha-Tubulin IgG
TUBA13-A 100 ul
EUR 578.4

Recombinant (E.Coli) Human Heat Shock Protein 90 alpha (hsp90/hsp90 alpha/dnak) protein control for Western
HSP903-C 100ul
EUR 343.2

Alpha 2-Macroglobulin (A2M), Human Plasma
A2MG15-N 1 mg
EUR 196.8

Cat Alpha-1-Acid Glycoprotein Protein, purified
A1AG16-N-25 25 ug
EUR 270

Alpha-1-Acid Glycoprotein Protein, Dog, purified
A1AG17-N-25 25 ug
EUR 270

Alpha-1-Acid Glycoprotein Protein, Rat, purified
A1AG19-N-25 25 ug
EUR 270

Goat Anti-Follicle Stimulating Hormone Alpha (FSH-Alpha) IgG aff pure
FSH13-A 1 mg
EUR 578.4

Goat Anti-human Chorionic Gonadotropin Alpha (hCG-Alpha) IgG aff pure
HCGA13-A 1 mg
EUR 343.2

Human Alpha Feto Protein (AFP) High Pure
AFP15-N 1 mg
EUR 854.4

Recombinant (E.Coli) Human Crystallin Alpha A
RP-611 20 ug
EUR 196.8

Recombinant (E.Coli) Human Crystallin Alpha B
RP-612 20 ug
EUR 196.8

Purified Human Chorionic Gonadotropin beta (HCG, beta) protein
HCG15-N-100 100 ug
EUR 343.2

Mouse Recombinant purified Resistin-Like protein alpha (RELM-alpha/FIZZ1)
RELMA15-R-25 25 ug
EUR 927.6

Mouse Recombinant purified Resistin-Like protein alpha (RELM-alpha/FIZZ1)
RELMA15-R-5 5 ug
EUR 388.8

He strongly inspired younger reproductive biologists who labored in his laboratory, and applauded the world-wide distinction of his scholar and affiliate, R. Yanagimachi, as a specialist in mammalian fertilisation. Finally, Chang’s continued emotions in the direction of his homeland are contrasted with the actuality of his American life after 1945, itself a examine in poignancy.

Study protocol: E-freeze - freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation.
in women undergoing in vitro fertilisation.

Study protocol: E-freeze – freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation.

Infertility impacts one in seven {{couples}}; many of these need in vitro fertilisation (IVF). IVF entails exterior hormones to stimulate a girl’s ovaries to produce eggs which might be harvested surgically. Embryos, created in the laboratory by mixing eggs with sperm, are grown in custom for a few days sooner than being modified inside the uterus (fresh embryo transfer).

Spare embryos are sometimes frozen with a view to transfer at a later degree in time – significantly if the preliminary fresh transfer does not consequence in a being pregnant. Despite enhancements in know-how, IVF success costs keep low with an complete reside starting value of 25-30% per remedy. Additionally, there are issues about nicely being outcomes for mothers and infants conceived by IVF, notably after fresh embryo transfer, collectively with maternal ovarian hyperstimulation syndrome (OHSS) and preterm provide.

It is believed that prime ranges of hormones all through ovarian stimulation could create a comparatively hostile setting for embryo implantation whereas rising the menace of OHSS. It has been steered that freezing all embryos with the intention of thawing and altering them inside the uterus at a later stage (thawed frozen embryo transfer) as a substitute of fresh embryo transfer, would possibly outcome in improved being pregnant costs and fewer issues. We goal to examine the clinical and cost effectiveness of fresh and thawed frozen embryo transfer, with the main goal of determining any distinction in the likelihood of having a healthful baby.

E-Freeze is a pragmatic, multicentre two-arm parallel group randomised controlled trial the place women aged ≥18 and < 42 years, with not lower than three good prime quality embryos are randomly allotted to acquire each a fresh or thawed frozen embryo transfer.

The main remaining result’s a healthful baby, outlined as a time interval, singleton, reside starting with relevant weight for gestation. Cost effectiveness may be calculated from a healthcare and societal perspective.E-Freeze will determine the relative benefits of fresh and thawed frozen embryo transfer in phrases of enhancing the likelihood of having a healthful baby. The outcomes of this pragmatic study have the potential to be straight transferred to clinical observe.ISRCTN registry

Study protocol: E-freeze - freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation.

Study protocol: E-freeze – freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation.

In vitro fertilisation/intracytoplasmic sperm injection previous 2020.

Over eight million infants have been born following IVF (in vitro fertilisation) and completely different artificial reproductive know-how (ART) procedures since Louise Brown’s starting 40 years in the previous. New enhancements have added a lot complexity to every clinical and laboratory procedures over the remaining four a few years. Translation of novel approaches from major science into clinical observe continues unabated, widening the applicability of ART to new groups of people and serving to boost every chances of healthful reside starting and affected particular person acceptability.

STAT Double Staining Reagent for Double staining o
NB327DB 25 ml
EUR 595
Description: STAT Double Staining Reagent for Double staining of Mouse and Goat antibodies, 450 plus slides

PI Staining Kit
abx097208-1Kit 1 Kit
EUR 276

DAPI Staining Kit
abx097206-1Kit 1 Kit
EUR 276

Coplin Staining Jar
08415-3 3sets
EUR 84

Cell Staining Buffer
E16FXP005 500 ml
EUR 40
Description: Available in various conjugation types.

Cell Staining Buffer
E-CK-A107-100mL 100 mL
EUR 20

Cell Staining Buffer
E-CK-A107-200mL 200 mL
EUR 35

Cell Staining Buffer
E-CK-A107-500mL 500 mL
EUR 60

ELVIS ID Staining Kit
SK-ELVIS-100 100 Tests Ask for price

ELVIS ID Staining Kit
SK-ELVIS-1000 1000 Tests Ask for price

ELVIS ID Staining Kit
SK-ELVIS-200 200 Tests Ask for price

ELVIS ID Staining Kit
SK-ELVIS-500 500 Tests Ask for price

Hoechst 33342 Staining Kit
abx097207-1Kit 1 Kit
EUR 276

?-Galactosidase Staining Kit
AKR-100 1 kit
EUR 518.4
Description: This simple assay measures the transfection efficiency of the LacZ gene using a simple staining protocol.

Cell Cycle Staining Kit
KTA2020-100T 100 T
EUR 119
Description: Abbkine Cell Cycle Staining Kit provides a convenient and accurate determination of the percentage of cells in each phase of the cell cycle.

Cell Cycle Staining Kit
KTA2020-50T 50 T
EUR 69
Description: Abbkine Cell Cycle Staining Kit provides a convenient and accurate determination of the percentage of cells in each phase of the cell cycle.

PI / RNase Staining Buffer
20-abx090619
  • EUR 326.40
  • EUR 276.00
  • 100 tests
  • 50 tests

Live NucRed staining kit
EGY069 >100T
EUR 210

HISTOCHEMISTRY STAINING TRAY
AT-12 12 PLACE - BLACK LID
EUR 226.1

HISTOCHEMISTRY STAINING TRAY
AT-24 24 PLACE - BLACK LID
EUR 342.21

HISTOCHEMISTRY STAINING TRAY
ATC-12 12 PLACE - CLEAR LID
EUR 226.1

HISTOCHEMISTRY STAINING TRAY
ATC-24 24 PLACE - CLEAR LID
EUR 342.21

Exosome fluorescent staining
S104 -
EUR 800

Live NucGreen staining kit
EGY068 >100T
EUR 210

Dead NucGreen staining kit
EGY070 >100T
EUR 210

GEL STAINING/INCUBATION BOX
SB-10 LIGHT SHIELDING
EUR 94.44

Ponceau S Staining Solution
B7778-100000 100 g
EUR 195.6

Ponceau S Staining Solution
B7778-50000 50 g
EUR 151.2

SDS-PAGE Staining Solution
GR103068 100 mL
EUR 58

Ponceau S Staining Solution
PW005 100ml
EUR 82.97

Ponceau S Staining Solution
41640009-1 500 mL
EUR 40.13

Ponceau S Staining Solution
41640009-2 1 L
EUR 58.16

Dual- Color AP Staining Kit
AP100D-1 100 Assays
EUR 494.4

EasyDip Slide Staining System
M900-12AS-ASSORTED 1 Case(s)
EUR 211.2

Red-Color AP Staining Kit
AP100R-1 50 Assays
EUR 314.4

Live/Dead Cell Staining Kit
55R-1434 100 tests
EUR 765.6
Description: Live/Dead Cell Staining Kit for use in the research laboratory

PAP PEN FOR IMMUNO STAINING
Z377821-1EA EACH
EUR 171.03

CometAssay Silver Staining Kit
4254-200-K 200 Tests
EUR 390.96

Nalgene Box Staining 13x13x5cm
BOX1040 EACH
EUR 48

PI Viability Staining Solution
E16FXP002 150 tests
EUR 40
Description: Available in various conjugation types.

Blue-Color AP Staining Kit
AP100B-1 50 Assays
EUR 203

Beta Galactosidase Staining Kit
55R-1541 250 assays
EUR 444
Description: Assay Kit for detection of Beta Galactosidase in the research laboratory

Disposable Slide Staining Trays
MIC5070 PK4
EUR 90

Staining Trough+Lid Rectangular
MIC6008 EACH
EUR 27.6

ProsiBlue Gel Staining Solution
P7300-050 500ml
EUR 208.8

Live-Dead Cell Staining Kit
K501-100 each
EUR 561.6

Live-Dead Cell Staining Kit
K2081-100 100 staining
EUR 552

Wheaton staining dishes 3 EA
S5017-3EA PK3
EUR 135.6

Live-Dead Cell Staining Kit
K2081-1000 1000T
EUR 140

Live-Dead Cell Staining Kit
K2081-500 500T
EUR 85

EZ-Quick Slide Staining Set
IW-2510 -
EUR 425

Staining Jar PP + Lid 10 Slide
MIC6002 EACH
EUR 67.2

Purple-Color AP Staining Kit
AP100P-1 100 Assays
EUR 235

Nerve Terminal Staining Kit V
70034 1SET
EUR 610.8
Description: Minimum order quantity: 1 unit of 1SET

Human Histochemistry Staining Kit
20-abx299039
  • EUR 1045.20
  • EUR 1462.80
  • EUR 678.00
  • 150 tests
  • 500 tests
  • 50 tests

Beta-Galactosidase Staining Kit
K802-250 each
EUR 352.8

Alkaline Phosphatase Staining Kit
K2035-50 50 assays
EUR 454.8

Beta-Galactosidase Staining Kit
K2182-250 250 assays
EUR 351.6

Lipid (Oil Red O) staining Kit
K580-24 each
EUR 542.4

Staining Jar W Lid 115x115x77mm
MIC6016 PK10
EUR 428.4

Manual Staining System (12 Wells)
IMS001 1 ea.
EUR 427.2

Red Active Caspase Staining Kit
K2052-100 100 assays
EUR 686.4

Red Active Caspase Staining Kit
K2052-25 25 assays
EUR 285.6

Alcian Blue (pH 2.5) Staining Kit
AFR-1 250 ml ea.
EUR 249.6

Alcian Blue (pH 2.5) Staining Kit
AFR-2 30 ml ea.
EUR 153.6

DAPI staining kit (ready to use) 
EGY0621 10mL
EUR 85

DAPI staining kit (ready to use) 
EGY0622 50mL
EUR 185

DNA Ploidy Analysis Staining Kit
K1439-1 each
EUR 705.6

DNA Ploidy Analysis Staining Kit
K1439-5 each
EUR 2402.4

Staining Dish with Cover Plastic
X24085 EACH
EUR 156

7-AAD Viability Staining Buffer
abx090617-100tests 100 tests
EUR 260.4

Simport EasyDip Staining Jar Blue
HIS0273 PK6
EUR 117.6

Simport EasyDip Staining Jar Pink
HIS0275 PK6
EUR 117.6

Plastic Coplin Staining Jars, each
IW-2501 -
EUR 8.6

Stayrightâ„¢ Purple HRP Staining Kit
45905-5mL 5 mL
EUR 109
Description: 3,3'-Diaminobenzidine (DAB) has been applied for decades as the most commonly used IHC chromogen because it is inexpensive and sensitive for routine applications.

Stayrightâ„¢ Purple HRP Staining Kit
45906-50mL